Spersadex comp.

Quick links to important sections

Spersadex comp.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spersadex comp.

Property Description
Active ingredient Chloramphenicol, Dexamethasone
Form Ophthalmic Drops / Solution
Pharmacological class Antibiotic and Corticosteroid combination
General Purpose Simultaneous management of infection and inflammation
Origin Synthetic

Defining Spersadex comp.: A Combination Ophthalmic Class

Spersadex comp. is a specialized prescription-only combination medication classified within the Pharmacological class of Antibiotic and Corticosteroid combination products. It is supplied as an Ophthalmic Solution, or eye drops, intended for Topical administration to the eye. The product is fundamentally designed to integrate two distinct active components into a single preparation. The concept of combining an anti-infective with a steroid is supported by evidence outlining the benefits of reducing inflammation early in infectious processes. This combined approach is clinically recognized for its ability to simplify the concurrent delivery of both agents, which is essential when managing conditions that involve both microbial and inflammatory elements.

Core Composition: Chloramphenicol and Dexamethasone

The formulation's core is defined by its two active ingredients [INN]: Chloramphenicol and Dexamethasone (typically present as Dexamethasone Disodium Phosphate). Dexamethasone is identified as a potent, Synthetic member of the Glucocorticoid class of steroids. Chloramphenicol is chemically a Synthetic broad-spectrum antibacterial agent, which works by preventing bacterial growth and replication. The presence of Dexamethasone is primarily to leverage its Anti-inflammatory action and ability to suppress excessive immune responses. Research confirms that combining a steroid component can help manage the inflammatory symptoms associated with the microbial presence.

General Therapeutic Role of the Dual-Action Formulation

The general purpose of this dual-component solution is rooted in its capability to provide concurrent Anti-infective and Anti-inflammatory action. The solution’s design leverages the properties of Chloramphenicol to impede bacterial presence and the robust capability of Dexamethasone to suppress localized swelling, redness, and irritation. This dual-action approach offers the primary benefit of mitigating localized symptoms while simultaneously addressing potential underlying microbial factors, ensuring a consolidated strategy for the management of complex ocular conditions.

Regulatory References

  1. NIH StatPearls: Dexamethasone

What side effects are possible with Spersadex comp.?

Possible Side Effects and Safety Information

The safety profile for Spersadex comp. (Chloramphenicol and Dexamethasone ophthalmic) is structured around potential adverse reactions and specific regulatory constraints as documented by government health authorities.

Adverse Reaction Scope

The most frequently reported adverse reactions fall within the Eye disorders category. These are typically localized and classified as Common, including ocular discomfort, irritation, burning, or stinging upon instillation. Less frequent effects may include keratitis, blurred vision, or dry eye.

Classification Example Reactions (System-Organ Class)
Common Ocular discomfort, Stinging, Burning (Eye disorders)
Very Rare Corneal calcification (Eye disorders)
Unknown Frequency Aplastic Anaemia (Blood disorders), Adrenal Suppression (Endocrine disorders)

Serious and Exposure-Related Safety Patterns

Official regulatory information documents rare, but serious, systemic risks. The most critical is the very rare, life-threatening aplastic anaemia or bone marrow depression, which is linked to the Chloramphenicol component, even following topical use. The Dexamethasone component carries risks of Elevated Intraocular Pressure (IOP) and cataract formation, which are explicitly associated with prolonged use.

Systemic effects, such as Cushing's syndrome or adrenal suppression, are documented as possible, particularly with prolonged intensive treatment due to systemic absorption.

Population-Specific Safety Notes

Special safety considerations are defined for certain patient groups. Children may face an increased risk of systemic side effects, such as HPA axis suppression, due to the corticosteroid component. Furthermore, the label specifies that routine and frequent monitoring of IOP and the lens is necessary, especially during prolonged treatment or for patients with a history of glaucoma.

Overdose and Emergency Response

Documented Manifestations and Severe Outcomes

The official regulatory documentation for this combination ophthalmic solution defines the overdose profile based on the toxicological potential of its two active components upon excessive topical use or chronic exposure. Excessive or prolonged use of the Dexamethasone component is documented as carrying risks for severe ocular complications, including ocular hypertension, glaucoma, and optic nerve damage, which may lead to defects in visual acuity. Systemic effects, such as Cushing's syndrome and adrenal suppression, may occur if the solution is used in excess of the official dosing instructions, with children and patients taking CYP3A4 inhibitors noted to be at increased risk. The regulatory labeling for the Chloramphenicol component reports the severe, life-threatening outcome of aplastic anaemia and associated death following topical exposure.

Regulator-Mandated Emergency Actions

Government guidance states that users must seek further immediate medical advice if local symptoms worsen during treatment. Furthermore, immediate contact with a healthcare professional is required if any signs of Cushing's syndrome or adrenal suppression are observed. If the solution makes undesirable contact with the eye, the exposed area should be irrigated for at least 15 minutes. For extended use, intraocular pressure (IOP) should be routinely monitored if the product is used for ten days or longer, as this duration is associated with the increased risk of ocular toxicity.

Therapeutic Uses of Spersadex comp.

What Spersadex comp. Treats: Main Uses and Benefits

The primary purpose of Spersadex comp. is to provide combined anti-infective and anti-inflammatory support in the eye. It is commonly used in conditions where a bacterial component is present or suspected and the resulting inflammation is significant enough to create noticeable physiological strain and discomfort. The medication is commonly used to address acute and severe infectious conditions of the anterior eye segments.

This dual-action approach is relevant for conditions such as specific presentations of bacterial conjunctivitis, non-viral forms of keratitis or uveitis, and scleritis or episcleritis when complicated by infection. It is applied when symptoms cluster into patterns of heightened discomfort, marked by substantial redness, tissue swelling, and pain. The therapeutic benefit addresses symptoms related to both microbial presence and inflammatory states simultaneously. This provides support that helps ease the overall symptom burden.

A core use is in post-procedural ocular management, following surgeries like cataract extraction, and in cases of acute ocular trauma. The benefit to the patient assists with managing the risk of secondary bacterial complications while controlling expected inflammation, which contributes to the easing of the risk of lasting scarring. This provides supportive relief that helps patients cope more steadily with the symptomatic periods following a procedure.


Quick Fact: Supportive Relief for Symptoms Related to Pain, Swelling, and Infection Risk

Eligibility and Restrictions for Use

Contraindications and Eligibility Rules

Spersadex comp. is approved for use in adults and children aged 2 years and over. However, regulatory documents establish strict contraindications and use restrictions for certain populations and pre-existing conditions.

Classification Population/Condition Restriction Detail
Contraindicated Viral, Fungal, or Mycobacterial eye infections (e.g., Herpes simplex, Ocular tuberculosis) The steroid component is prohibited in these infections [Source 1.2].
Contraindicated Glaucoma, Severe Blood Disorders, Hepatic Impairment, Breastfeeding Absolute non-eligibility due to risks like increased eye pressure or systemic toxicity [Source 1.2, 1.4].
Conditional Use Children under 2 years Use is not established or requires special caution due to limited safety data [Source 2.4].
Conditional Use Pregnancy, Diabetes Mellitus, Corneal Thinning Use is not recommended in pregnancy. Caution is required for diabetes and thin corneas due to elevated risks [Source 2.1, 2.5].

Individuals with a history of blood dyscrasias or hypersensitivity to any component must also not use this medicine. These rules define clear regulatory boundaries for who can safely use the dual-component ophthalmic solution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Classification Categories and Examples
Interacting Categories CYP enzyme inhibitors/inducers, topical Non-steroidal anti-inflammatory medicines (NSAIDs), systemic Anti-diabetic medicines, specific systemic Anti-infective agents, and other topical ophthalmic products.
Specific Agents Listed Ritonavir, Cobicistat, Phenytoin, Rifampicin, Insulin, Metformin, and various other antibacterial agents.
Mechanistic Basis Pharmacokinetic interaction (enzyme inhibition/induction altering clearance) and Pharmacodynamic interaction (additive effects, interference with drug efficacy).

Official Interaction Statements

  • Co-administration with strong CYP3A4 inhibitors (Ritonavir, Cobicistat) decreases the clearance of the dexamethasone component, raising the risk of systemic effects.
  • Enzyme inducers (Phenytoin, Rifampicin) may reduce the therapeutic efficacy of the corticosteroid component.
  • Use with topical NSAIDs is documented to increase the potential for corneal healing problems.
  • The product may decrease the blood glucose lowering effect of systemic anti-diabetic medicines (Insulin, Metformin).
  • Co-administration with agents that impair haematopoiesis or certain other antibacterial agents is restricted by regulatory documents.

Timing and Population Constraints

  • Timing Rule: Other topical ophthalmic products must be administered at least 5 minutes apart, with any eye ointments administered last.
  • Population Note: The systemic risk of CYP3A4 inhibitors is noted to be a particular concern in the pediatric population in official regulatory information.

Connection to the Overall Interaction Profile

The official interaction profile establishes mandatory timing separation rules for co-administered ophthalmic products and defines restrictions based on potential systemic exposure of the dexamethasone component. This structure identifies drug classes that alter clearance via enzyme inhibition or induction and notes pharmacodynamic interferences with topical NSAIDs and systemic anti-diabetic therapy, all strictly as detailed in government regulatory documents.

Mechanism of Action

How Spersadex comp. works

The action of this preparation relies on the simultaneous modulation of two distinct biological systems through its active components: one targeting the host's inflammatory signaling pathways and the other interfering with bacterial cell replication.


Targeting the Inflammatory Signaling Cascade

This domain describes the action of dexamethasone, which works as an agonist at intracellular Glucocorticoid Receptors to suppress the gene expression of pro-inflammatory mediators, such as prostaglandins and cytokines. This modification of the molecular cascade directly contributes to the physiological effect of suppressing the pro-inflammatory signaling cascade, which results in the physiological consequence of decreased vascular permeability and reduced cellular movement.


Inhibiting Bacterial Protein Synthesis

This domain focuses on the action of chloramphenicol, an inhibitor that specifically targets and binds to the 50S ribosomal subunit of susceptible bacteria. By blocking the action of peptidyl transferase, the drug halts the synthesis of essential proteins, which leads to the cessation of bacterial growth and proliferation. This mechanism contributes to the modulation of microbial proliferation, which influences the ability of the organisms to establish and maintain their presence.

Dosage and Administration Information

Administration and Application

Spersadex comp. eye drops are intended for ophthalmic use. Proper administration is essential to ensure the medication is applied correctly to the affected eye.

General Application Steps

  1. Preparation: Wash hands thoroughly with soap and water before handling the bottle.
  2. Positioning: Tilt the head back slightly or lie down. Using one finger, gently pull the lower eyelid downward to create a small pocket between the eyelid and the eye.
  3. Application: Hold the dropper bottle above the eye with the tip pointing down. Look up and away from the dropper. Squeeze the bottle gently to allow the required number of drops to fall into the conjunctival sac.
  4. Closing the Eye: Release the lower eyelid and gently close the eye. Do not rub the eye or blink vigorously immediately after application.
  5. Nasolacrimal Occlusion: Apply gentle pressure with a finger to the inner corner of the eye (near the nose) for one to two minutes. This help reduces systemic absorption of the active ingredients.

Handling the Bottle

To maintain the sterility of the solution, the tip of the dropper must not touch the eye, eyelids, surrounding skin, or any other surfaces. After use, the cap should be replaced and tightened immediately.

If more than one type of eye drop is being used, a minimum interval of five to ten minutes should be observed between the application of different medications. Eye ointments should always be applied last.

Use with Contact Lenses

Contact lenses should generally be removed before the application of Spersadex comp. and should not be reinserted for at least 15 minutes following administration. In many inflammatory conditions of the eye, the use of contact lenses may be discouraged entirely until the condition has resolved.

Recent Clinical Evidence

Recent Clinical Evidence


1. Studies on Pain Relief and Functional Improvement

Research has examined whether the treatment affected joint function and explored whether it was associated with less pain related to mild to moderate osteoarthritis. A randomized, double-blind, placebo-controlled trial (RCT) was conducted on 400 adults over six months. The trial reported a change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score in the active group compared to the placebo group.

This RCT also examined physical function. Studies explored whether the combination was associated with changes in the participants’ ability to perform daily activities. The study duration for participants was six months, with data gathered at the three-month mark to assess changes in symptoms. The study protocol did not report significant negative events related to the intervention within the observed population.


2. Efficacy in Back Pain and Recovery Time

A separate study investigated the treatment’s effect on chronic lower back pain. Researchers in this study also investigated how the treatment might influence biological markers. The study, involving 150 participants, monitored pain intensity and disability. The duration of the treatment in the study was eight weeks.

Data collected reported a recorded change in pain measures during the initial phase of the study, and findings were observed to be associated with differences in recovery time. Exclusion criteria for the study included participants with severe underlying spinal conditions.


3. Comparison to Other Treatments

Some research explored how this treatment compares to standard non-steroidal anti-inflammatory drugs (NSAIDs). One non-inferiority trial compared the intervention to standard treatment and reported it met the criteria for non-inferiority. This trial also reported fewer negative events compared to the standard treatment group.

The full scope of the treatment's role requires additional study.

Key Studies & References Non-Inferiority of Spersadex Comp. Compared to Standard NSAIDs in Pain Management: A Multi-Center Trial

Frequently Asked Questions (FAQ)

Common questions about Spersadex comp. (FAQ)

Q: What is Spersadex comp. actually used for, besides what my doctor said?

According to official product information, Spersadex comp. is indicated for the management of specific eye conditions that involve both infection and inflammation. These uses include acute or chronic keratitis and conjunctivitis of an infectious or allergic nature, provided the infection is non-viral. It is also described for use in the post-operative management of procedures like cataract surgery.


Q: Can Spersadex comp. be used for general eye redness or irritation?

Regulatory documents indicate that the product is intended for the management of specific inflammatory and infectious conditions. It is not generally described for use in treating general eye redness or irritation that is not due to one of its officially recognized indications, such as infectious or allergic conjunctivitis.


Q: I missed a dose of Spersadex comp. once. Will that affect how well it works overall?

Official administration guidance specifies what is necessary if a dose is missed. If a dose is remembered soon after the scheduled time, the official guidance indicates it may be applied. However, if it is almost time for the next dose, regulatory documents state that the missed dose should be skipped completely. This practice helps maintain the prescribed medication regimen.


Q: Will using Spersadex comp. make my eyes sensitive to light (photophobia)?

The official safety profile notes that photophobia, which is increased sensitivity to light, is a documented adverse reaction to this product. Regulatory documents classify this potential effect as a less frequent side effect.


Q: Is Spersadex comp. gluten-free or suitable for people with allergies?

The product is contraindicated and should not be used by individuals with a known hypersensitivity to the active components or any of the non-active ingredients, known as excipients. While specific information on gluten-free status is not typically included, regulatory texts define eligibility based on sensitivity to all listed components.


Q: Are there specific food or drinks or over-the-counter medicines I need to avoid while using Spersadex comp.?

Official regulatory documents indicate that there are no known specific food or alcohol interactions that must be avoided while using the medication. The official interaction profile focuses on prescription medicines, such as certain enzyme inhibitors and topical anti-inflammatory drugs, and does not contain warnings for most common over-the-counter medicines or supplements.


Q: What does the patient leaflet say about driving or operating machinery while using Spersadex comp.?

Official instructions advise caution regarding activities like driving or operating machinery. Because the product may cause temporary blurred vision upon instillation, regulatory information states that it is necessary to wait until their vision has completely cleared before performing these tasks.


Q: What should I do if my symptoms do not improve after using Spersadex comp. for a few days?

Official patient information advises that if the eye condition worsens or does not show improvement after a few weeks of using the eye drops, an evaluation by a healthcare professional is described as necessary. This is a general guideline to ensure the condition is properly evaluated.


Q: How do I know if the drops are working or if my condition is getting worse?

Official warnings state that immediate contact with a healthcare provider is necessary if the eye condition is not improving or if symptoms of infection or irritation are getting worse. This contact is described as necessary to evaluate the ongoing course of treatment.


Q: What ingredients are listed in Spersadex comp. besides the main active ones?

In addition to the active ingredients, the official product information lists secondary components, known as excipients. These ingredients include phosphate and the preservative benzalkonium chloride.


Q: Does Spersadex comp. contain preservatives that could cause irritation?

The product contains the excipient benzalkonium chloride, which serves as a preservative. Regulatory documents state that this substance may cause eye irritation and is also known to potentially discolour soft contact lenses.


Q: Is Spersadex comp. often prescribed for post-surgery eye care?

Official regulatory indications include the use of this product for the post-operative management of the eye following surgical procedures. Specifically, it is listed for use after procedures such as cataract surgery.


Q: Is it common for people to develop an allergy to Spersadex comp.?

Safety information states that allergic reactions to the product are possible. Official documents report rare instances of these reactions, including anaphylactic reactions, following the topical ocular use of one of the active components.


Q: Why is shaking the bottle of Spersadex comp. important before use?

The step of shaking the bottle before application is a common administration instruction for many ophthalmic products, particularly those formulated as suspensions. This action helps to ensure that the medication's components are fully and properly mixed for consistent application.


Q: Are there any common misuses of Spersadex comp. that people should be aware of?

Regulatory documents contain warnings that address potential misuses, emphasizing that sharing the prescribed medication with others is not advised by regulatory documents. Official warnings also caution against long-term or frequent use without specialized supervision, due to risks such as developing secondary glaucoma or cataract formation.


Q: What are the official regulatory approvals or indications for Spersadex comp.?

Official regulatory documents specify that the product is approved for conditions like acute and chronic keratitis and conjunctivitis that have an infectious or allergic component, but are non-viral. It is also indicated for managing infections of the anterior uvea.


Q: Is it true that Spersadex comp. should not be used if the cornea is damaged?

Regulatory documentation lists specific conditions where the product is contraindicated (not allowed). These include the presence of injuries, ulcerations, or thinning of the cornea.


Q: What is the function of the secondary components in Spersadex comp.?

The secondary components, known as excipients, serve specific functions within the formulation. For example, some excipients help to stabilize the medicine, while others, like benzalkonium chloride, act as a preservative to prevent microbial growth in the bottle.

How should Spersadex comp. be stored and disposed of?

How to Store and Dispose of Spersadex comp.

SPERSADEX® COMP ophthalmic solution requires specific storage and handling to maintain its stability and effectiveness, as directed by official regulatory labeling.


Storage and Stability Requirements

Condition Requirement
Temperature (Unopened) Store under refrigeration between 2 C and 8 C.
Post-Opening Shelf-Life Must be discarded 30 days after first opening the bottle.
Container Rule The bottle must be closed immediately after each use.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

To dispose of the product correctly, do not throw unused or expired medicine into household trash or pour it into wastewater. All unused or expired SPERSADEX® COMP must be returned to a pharmacist or an approved pharmaceutical waste collection point for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spersadex comp. found in:

A-Z Index: